NON-SMALL-CELL LUNG CANCER

This trial tests whether a gentler suction level (-2 cmH2O) on chest tubes after keyhole lung cancer surgery works as well as the standard stronger suction (-10 cmH2O). The goal is to see which setting allows tubes to be removed sooner and causes fewer complications. About 230 ad…

This phase II trial tests whether a low-dose, frequent schedule of the chemotherapy drug vinorelbine, taken orally, can boost the effects of the immunotherapy atezolizumab in people with stage IV non-small cell lung cancer. The study enrolls adults whose cancer has progressed aft…

This Phase 3 trial tested a new targeted therapy, lazertinib, against the standard drug gefitinib in 393 people with advanced EGFR-mutated non-small cell lung cancer. The goal was to see if lazertinib could keep cancer from growing longer. Participants took either lazertinib or g…

This large phase 3 trial tested whether the immunotherapy drug pembrolizumab (Keytruda) could help people with a specific type of advanced lung cancer live longer than standard chemotherapy. Over 1,200 participants with PD-L1 positive non-small cell lung cancer were randomly assi…

This phase 2 trial tested whether adding relatlimab to the standard immunotherapy nivolumab plus chemotherapy could shrink tumors better in people with advanced or recurrent non-small cell lung cancer. About 468 participants received either the two-immunotherapy combo with chemo …

This early-phase trial tested a new drug called RO7496353 combined with an immunotherapy (atezolizumab) and sometimes chemotherapy in 102 people with advanced lung, stomach, or pancreatic cancer. The main goal was to check safety and side effects. Researchers also looked at how t…

This study tested a drug called PF-06801591 in 155 people with advanced solid tumors or non-small-cell lung cancer. The drug works by blocking a protein that stops the immune system from attacking cancer cells. The goal was to check safety, how the drug moves through the body, an…

This phase 2 study tested three different drug combinations in 151 people with advanced non-small cell lung cancer that had not been treated before. The drugs help the immune system attack cancer cells. Researchers measured how many patients' tumors shrank or stopped growing, and…

This early-phase study tested a personalized cancer vaccine (RO7198457) in 273 patients with advanced solid tumors like melanoma, lung, and breast cancer. The vaccine was given alone or with an immunotherapy drug (atezolizumab) to see if it was safe and how the body responded. Th…

This early-phase study tested a combination of two drugs, bexarotene and Iressa, in 6 people with advanced non-small cell lung cancer who had already tried standard treatments. The goal was to see if the combination was safe and could help control the disease. The study looked at…

This study tested an oral drug called PLB1001 in 145 people with advanced non-small cell lung cancer whose tumors have a specific genetic change (c-Met dysregulation). The main goal was to see how many patients' tumors shrank or disappeared. The drug is taken twice daily and aims…

This completed Phase 4 trial tested two different doses of chemotherapy (standard and low-dose) combined with the immunotherapy drug Sintilimab in 20 people with advanced squamous non-small cell lung cancer. The goal was to see if the lower-dose combination could shrink tumors an…

This study looked at whether giving immunochemotherapy in the morning or afternoon affects how long people with advanced non-small cell lung cancer live without their disease getting worse. 210 patients were randomly assigned to receive treatment before or after 3 PM. The goal is…

This early-stage trial tested a new drug called PF-07257876 in 29 people with advanced lung, head/neck, or ovarian cancers that had stopped responding to other treatments. The drug is a bispecific antibody designed to help the immune system attack cancer cells. The main goals wer…

This phase 3 study tested alectinib against crizotinib in 303 people with advanced ALK-positive non-small cell lung cancer who had not received prior treatment. Participants took one of the two drugs twice daily until their cancer worsened or side effects became too severe. The m…

This study tested a new drug called XTX202 in 95 people with advanced solid tumors that had not responded to standard treatments. The goal was to check safety, find the right dose, and see if the drug could shrink tumors. The trial is now complete.

This study tested whether combining two targeted drugs, savolitinib and osimertinib, works better than standard chemotherapy for people with advanced non-small cell lung cancer that has a specific genetic change (MET amplification) and has stopped responding to initial treatment.…

This study tested whether adding an experimental drug (CCR2/5-inhibitor or anti-IL-8) to the immunotherapy nivolumab before and after surgery could help shrink tumors and improve long-term survival in people with non-small cell lung cancer or liver cancer. 48 participants receive…

This phase 3 trial tested whether adding plinabulin to the chemotherapy drug docetaxel helps people with advanced non-small cell lung cancer live longer. 559 participants who had already tried one or two prior treatments received either the combination or docetaxel alone. The stu…

This study tested whether adding the immunotherapy drug camrelizumab to standard chemotherapy and radiation helps people with advanced lung cancer whose disease has spread to the brain. The trial included 60 patients who had not received chemotherapy before. Researchers measured …

This phase 3 study tested whether adding the immunotherapy drug cemiplimab to standard chemotherapy helps people with advanced non-small cell lung cancer live longer. The trial enrolled 789 participants and compared different drug combinations. The main goal was to see if the com…

This phase 2 study tested whether adding the targeted drug erlotinib to standard chemotherapy (docetaxel) works better than chemotherapy alone for people with advanced non-small cell lung cancer whose first treatment stopped working. 156 participants were randomly assigned to one…

This study tested a new drug (ningetinib) combined with an existing targeted therapy (gefitinib) in 108 people with advanced lung cancer whose cancer had stopped responding to previous treatments. The goal was to find the safest dose and see if the combination could shrink tumors…

This study tested an experimental drug called CBX-12 in 69 adults with advanced solid tumors (like ovarian, lung, breast, or colon cancer) that had stopped responding to standard therapies. The main goals were to check the drug's safety, find the best dose, and see if it could sh…

This early-stage study tested a custom-made yeast vaccine designed to train the immune system to recognize and attack leftover cancer cells. Five adults with various cancers (like colorectal, breast, or lung) who had completed initial treatment received the vaccine. The goal was …

This early-stage study tested a new drug called BI 765049, alone or combined with another drug (ezabenlimab), in 21 Asian adults with advanced solid tumors (stomach, colorectal, pancreatic, liver, head and neck, or lung cancer) that have a specific marker called B7-H6. The main g…

This phase 2 study tested whether adding tiragolumab to the standard immunotherapy atezolizumab helps people with advanced non-small cell lung cancer who have not had chemotherapy. 135 participants received either the combination or a placebo plus atezolizumab. The main goals wer…

This study tested a new way to deliver high-dose radiation to small lung tumors in just one day, instead of the usual two to three weeks. Ten patients with early-stage lung cancer or limited lung metastases received a single session of stereotactic body radiotherapy (SBRT) using …

This study tested a new oral drug called ensartinib (X-396) for the first time in humans. It involved 131 people with advanced solid tumors, including those with ALK-positive non-small cell lung cancer. The goal was to find the safest dose and see if the drug could shrink tumors.…

This study tested whether adding a bronchoscopy-guided treatment to standard immunotherapy and chemotherapy could help people with advanced central non-small cell lung cancer. The trial included 33 adults whose cancer could not be surgically removed. The goal was to see if the tr…

This study tested whether customizing chemotherapy based on specific gene mutations (EGFR and BRCA1) could improve outcomes for 153 patients with advanced lung adenocarcinoma. Participants received treatments matched to their tumor's genetic profile. The goal was to see if this p…

This trial tested several targeted drugs in people with non-small cell lung cancer whose tumors had specific genetic changes. The goal was to see if these drugs could shrink tumors or delay cancer growth. Over 400 participants received treatment based on their tumor's genetic pro…

This early-phase study tested whether combining the immunotherapy drug pembrolizumab with standard palliative radiation is safe for people with advanced lung cancer. Twenty-four participants received different doses of pembrolizumab alongside radiation, then continued pembrolizum…

This phase 2 trial tested a combination of two drugs, tucidinostat and tislelizumab, as a first treatment for people with a type of advanced lung cancer that has a specific marker (PD-L1 positive). The study involved 118 participants and aimed to see if the combo could delay canc…

This early-stage trial tested an experimental drug called CTX-471, given alone or with the approved drug Keytruda, in 100 adults with advanced cancers like lung cancer, melanoma, and head and neck cancer. The goal was to see if the combination is safe and tolerable for patients w…

This Phase 3 trial tested whether adding custirsen to the chemotherapy drug docetaxel helps people with advanced non-small cell lung cancer live longer. The study involved 664 patients who had already tried one platinum-based treatment. Researchers compared survival between those…

This early-phase trial tested the safety of combining two drugs—L-NMMA and pembrolizumab (Keytruda)—in 12 adults with various advanced cancers. Pembrolizumab helps the immune system recognize cancer cells, while L-NMMA may remove a chemical barrier that blocks immune attack. The …

This completed study looked at how safe sotorasib is for Chinese patients with a certain type of advanced lung cancer (KRAS G12C-mutated NSCLC). 102 patients who had already tried other treatments took sotorasib pills daily. Researchers tracked side effects and how long patients …

This early-phase trial tested the drug everolimus (RAD001) alongside radiation therapy in 26 people with advanced non-small cell lung cancer that could not be surgically removed. The goal was to find a safe dose and check for side effects. Participants received everolimus weekly …

This study tested the drug durvalumab in 446 people with advanced non-small cell lung cancer who had already tried at least two prior treatments. The goal was to see if the drug could shrink tumors or slow the disease. Participants received infusions every two weeks for up to 12 …

This study tested a new drug called STRO-002 in 19 Chinese adults with advanced ovarian, endometrial, or other solid tumors that had not responded to prior treatments. STRO-002 is an antibody-drug conjugate, meaning it combines a targeted antibody with a chemotherapy drug to deli…

This study tested an experimental drug called BMS-986016 (anti-LAG-3) alone or combined with nivolumab in people with advanced solid tumors that had spread or couldn't be removed by surgery. It included several cancer types like lung, stomach, liver, kidney, bladder, head and nec…

This study tested a combination of two targeted drugs, encorafenib and binimetinib, in 98 people with advanced non-small cell lung cancer that has a specific BRAF gene mutation. The goal was to see if the drugs could shrink tumors and how safe they were. Participants had either n…

This phase 2 trial tested the drug DS-1062a in 137 adults with advanced or metastatic non-small cell lung cancer that has specific genetic changes and has worsened after targeted therapy and chemotherapy. The main goal was to see how many patients' tumors shrank or disappeared. T…

This phase 3 trial tested the drug pembrolizumab (Keytruda) against a placebo in 1,177 people with early-stage non-small cell lung cancer who had already had surgery. The goal was to see if pembrolizumab could delay the cancer from coming back. Participants received either the dr…

This study tested whether combining two drugs, brentuximab vedotin and pembrolizumab, can shrink tumors in people with advanced melanoma, lung cancer, or head and neck cancer that has spread. About 161 adults took part. The main goal was to see how many patients had their tumors …

This study tested whether a short course of radiation to one tumor site could help immunotherapy drugs work better in people with advanced lung or head/neck cancers. 76 participants received radiation within two weeks of starting their immunotherapy. The main goal was to see if t…

This study tested a combination of two drugs—NT-I7 (efineptakin alfa) and pembrolizumab (Keytruda)—in 215 people with advanced solid tumors that had stopped responding to treatment. The goal was to check safety, find the right dose, and see if the combo could shrink tumors. The t…

This study tested a combination of two experimental drugs, AK112 and AK117, with or without chemotherapy, in 154 people with advanced solid tumors. The goal was to see if the combo could shrink tumors and control the disease. The trial has finished, and researchers are now lookin…

This trial tested a new drug called AK112 in 108 people with advanced non-small cell lung cancer. The drug targets both PD-1 and VEGF to attack cancer cells and cut off their blood supply. The study aimed to see if the drug shrinks tumors and how safe it is. Participants had stag…

This study tested a combination of two drugs—nivolumab (Opdivo) and ALT-803—in 67 people with advanced non-small cell lung cancer that had not responded to prior treatments. The goal was to find a safe dose and see if the combination could shrink tumors. The trial is now complete…

This phase 3 trial tested whether adding lenvatinib to pembrolizumab helps people with untreated advanced non-small cell lung cancer whose tumors have PD-L1 levels of 1% or higher. Over 600 participants received either the combination or pembrolizumab alone. The study measured ho…

This study tested giving the immunotherapy drug tislelizumab, alone or with other drugs, before surgery for people with stage II to IIIA non-small cell lung cancer that could be removed. The goal was to see if this approach could shrink tumors and improve outcomes. 121 adults too…

This early-phase trial tested whether injecting the chemotherapy drug cisplatin directly into lung tumors (during a bronchoscopy) is safe for people with early-stage, resectable non-small cell lung cancer. Only 6 participants were enrolled, and the main goal was to find the highe…

This study tested whether a procedure called local ablative therapy (LAT) can help control metastatic non-small cell lung cancer (NSCLC) when a blood test shows signs of remaining cancer (minimal residual disease, or MRD). 37 patients with stage IV NSCLC received LAT to all visib…

This early-phase study tests two experimental drugs, BI 765049 and ezabenlimab, in adults with advanced solid tumors like colorectal, lung, and pancreatic cancer. The main goal is to find the highest safe dose of BI 765049 alone and in combination with ezabenlimab. Participants r…

This study looked at whether a special care plan led by a geriatrician and a nurse could improve survival and quality of life for older adults (70+) with advanced cancer. 792 patients with breast, colorectal, lung, prostate, bladder, ovarian cancer, or lymphoma took part. The app…

This study tested whether adding a new drug called tiragolumab to the standard immunotherapy atezolizumab works better than atezolizumab alone for people with advanced non-small cell lung cancer that has not been treated before. About 620 participants with high levels of a protei…

This study looked at whether switching from the immunotherapy durvalumab to the targeted drug sotorasib can better control locally advanced non-small cell lung cancer in patients with a KRAS G12C mutation and signs of remaining cancer (minimal residual disease). Ten participants …

This study tested a combination of two drugs—pembrolizumab (Keytruda) and Imprime PGG—in 35 people with advanced non-small cell lung cancer whose disease had worsened after initial treatment. The goal was to find a safe dose and see if the combination could slow cancer growth. Th…

This study tested whether adding two immunotherapy drugs (nivolumab and ipilimumab) after standard chemoradiation could better control stage III lung cancer compared to nivolumab alone. 105 patients were randomly assigned to one of the two treatment groups. The main goal was to s…

This early-phase trial tested a combination of two drugs—pembrolizumab (an immunotherapy) and nintedanib (a drug that blocks blood vessel growth)—in 196 adults with advanced solid tumors that had worsened after standard treatment. The main goal was to find the safest dose of nint…

This study tested a daily pill called AZD9291 in 171 people from Asia Pacific with advanced lung cancer that has a specific genetic change (T790M mutation). The goal was to see if the drug could shrink tumors and control the disease after other treatments stopped working. Researc…

This phase 2 trial tested a new drug called gimistotug (BGB-A445) combined with either another experimental drug (BGB-15025) or the standard chemo docetaxel in 35 people with advanced non-small cell lung cancer. All participants had already tried an immunotherapy and chemotherapy…

This study tested a new way of giving radiation therapy combined with immunotherapy for people with advanced non-small cell lung cancer that does not have certain genetic mutations. The goal was to see if mixing high-dose and low-dose radiation could help the immune system fight …

This phase 2 trial tested a combination of two oral drugs, RMC-4630 and sotorasib, in 47 adults with advanced KRASG12C-mutant non-small cell lung cancer that had progressed after standard treatments. The goal was to see if the combination could shrink tumors. The study is now com…

This early-phase study tested a combination of two experimental drugs (BGB-283 and PD-0325901) in 91 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and see if the drugs could shrink tumors. The trial is no…

This phase 3 trial tested whether adding the immunotherapy drugs nivolumab (Opdivo) and ipilimumab (Yervoy) to standard chemotherapy could improve outcomes for people with early-stage non-small cell lung cancer that can be surgically removed. The study enrolled 505 participants a…

This early-phase study tested a new drug called BAT8006 in 216 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the best dose for future studies. This is not a cure, but a step toward better control…

This study tested whether giving personalized radiation doses based on PET scans during treatment could improve local control in patients with inoperable stage III non-small cell lung cancer. 158 participants received either standard radiation or a higher, tailored dose to areas …

This early-stage trial tested an oral drug called JAB-3312 in 40 adults with advanced solid tumors (like lung, colon, or breast cancer) that had stopped responding to standard treatments. The main goals were to find a safe dose and check for side effects. Researchers also looked …

This early-phase trial tested an experimental drug called ezabenlimab, alone or combined with another drug (BI 754111), in 146 Asian patients with advanced solid tumors. The main goals were to check safety, find the right dose, and see if the combination shrinks tumors in cancers…

This phase 3 trial tested whether adding two immunotherapy drugs (nivolumab and ipilimumab) to standard chemotherapy helps people with stage IV non-small cell lung cancer live longer. About 719 patients who had not received prior treatment took part. The study compared the combin…

This study tested a new drug (TJ004309) combined with an approved immunotherapy (atezolizumab) in 25 people with advanced ovarian, head and neck, lung, gastrointestinal, or triple-negative breast cancers. The goal was to see if the combination could shrink tumors. Participants ha…

This early-stage trial tested a new treatment for people with advanced non-small cell lung cancer that had grown after standard therapy. Researchers took patients' own immune cells, genetically modified them to recognize and attack cancer cells, and infused them back after chemot…

This early-stage study tested whether adding PB101 (a patient's own natural killer cells) to standard targeted therapy is safe for people with advanced EGFR-mutated non-small cell lung cancer. Eight adults with stage IIIB/IV disease received the combination. The main goal was to …

This early-phase trial tested a personalized immunotherapy for people with advanced solid tumors. Doctors removed a sample of each patient's tumor, grew the immune cells (TILs) in a lab, and then infused them back along with another drug. The goal was to see if this approach is s…

This early-stage study tested a new drug called BAT1308 in 59 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to find a safe dose and check for side effects. Researchers also looked at how the drug moves through the body. Th…

This study tested whether a subcutaneous (under-the-skin) injection of the immunotherapy drug atezolizumab works as well as the standard intravenous (IV) infusion in people with advanced non-small cell lung cancer who had already tried platinum-based chemotherapy. The trial enrol…

This early-phase study tested adding the drug pirfenidone to standard chemotherapy for people with advanced non-small cell lung cancer. The main goals were to find a safe dose and see if the combination could shrink tumors. 48 participants were enrolled, and the study is now comp…

This study looked at whether giving palliative radiation to several tumor sites before starting standard immunotherapy and chemotherapy can help people with metastatic non-small cell lung cancer. Fifty adults with cancer that had spread and low PD-L1 levels received radiation to …

This study tested a new experimental drug called JS004, combined with another immunotherapy (toripalimab) and standard chemotherapy, in 119 people with advanced lung cancer. The goal was to see if the combination is safe and might help shrink tumors. The trial has finished, but r…

This study tested whether using a non-invasive ventilation machine for at least 7 days before lung cancer surgery could reduce lung and heart complications. The trial included 300 patients with lung cancer who also had breathing problems, obesity, or heart failure. The goal was t…

This study tested a combination of two drugs, atezolizumab and bevacizumab, as the first treatment for people with advanced non-squamous lung cancer that has a high number of genetic mutations. The goal was to see if this drug pair could slow down cancer growth. The trial enrolle…

This early-phase trial tested several combinations of cancer drugs, including niraparib, TSR-042, bevacizumab, and various chemotherapies, in 60 patients with advanced or metastatic cancer. The main goal was to find safe doses for future studies. The trial has been completed, but…

This study tested a drug called trastuzumab deruxtecan in 152 people with advanced non-small cell lung cancer that has a specific genetic change (HER2 mutation) and has stopped responding to standard chemotherapy. The drug is given by IV every three weeks and aims to shrink tumor…

This early-phase trial tested whether adding copanlisib to the standard immune therapy durvalumab is safe for people with stage III non-small cell lung cancer that cannot be removed by surgery. The study enrolled 11 participants who had already received chemotherapy and radiation…

This Phase 2 trial tested whether adding the experimental drug OSI-906 to the standard targeted therapy erlotinib (Tarceva) could help people with advanced non-small cell lung cancer that has a specific EGFR gene mutation. The study enrolled 88 people who had not received prior c…

This study tested giving the cancer drug nivolumab as a shot under the skin (instead of through an IV) to people with advanced cancers like lung, kidney, melanoma, liver, and colorectal cancer. The main goal was to see how the drug moves in the body and to check for side effects.…

This study tested an experimental drug called BDB001 in people with advanced solid tumors (like skin, lung, or kidney cancer) that had stopped responding to standard immunotherapy. The goal was to see if BDB001 could shrink tumors or slow their growth. Only one person took part, …

This early-phase study tested an experimental drug called GDC-1971 combined with either osimertinib (for lung cancer) or cetuximab (for colorectal cancer) in 10 people with advanced cancers that had spread. The main goal was to check safety and find the right dose. Researchers al…

This early-phase trial tested a new drug called CHS-388 in 145 people with advanced solid tumors (kidney, liver, or lung cancer) that had stopped responding to standard treatments. CHS-388 is an antibody that blocks a protein called IL-27, which may help the immune system fight c…

This study tested whether combining the immunotherapy drug nivolumab with another drug (ipilimumab) or with standard chemotherapy could help people with advanced non-small cell lung cancer live longer or keep their cancer from growing. About 2,700 patients who had not received pr…

This study tested a daily oral drug called sotorasib in 42 adults with advanced (stage IV) non-small cell lung cancer that has a specific KRAS G12C mutation and has not been treated before. The goal was to see how well the drug shrinks tumors and how safe it is. Participants rece…

This early-phase study tested a new drug called BAY 2862789 in 45 people with advanced solid tumors, including non-small cell lung cancer. The drug works by activating immune cells to fight cancer. The main goals were to check safety, find the best dose, and see how the drug move…

This phase II trial tested a combination of two immunotherapy drugs (nivolumab and ipilimumab) plus chemotherapy (paclitaxel) in 46 people with untreated metastatic non-small cell lung cancer. The goal was to see if the mix could slow cancer growth and be safe. Results may point …

This early-stage trial tested a new drug called vibostolimab, either alone or combined with other cancer drugs, in 474 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find the right dose, and see if the dr…

This early-phase study tested a combination of two immunotherapy drugs, BGB-A445 and tislelizumab, in 204 people with advanced solid tumors including lung, head and neck, and nasopharyngeal cancers. The main goals were to check safety and find the best dose. The trial is now comp…

This phase 2 trial tested the drug serplulimab (an immunotherapy) combined with standard chemotherapy in 30 people with stage II-IIIA non-small cell lung cancer that could be surgically removed. The treatment was given before and after surgery to see if it could shrink tumors and…

This early-phase study tested an experimental drug called ABBV-CLS-579, given alone or with other cancer treatments, in 101 adults with advanced solid tumors that had stopped responding to standard therapy. The main goal was to find safe and tolerable doses, not to prove the drug…

This phase 2 trial tested a new drug called BA3011, alone or with an immunotherapy, in 85 adults with advanced non-small cell lung cancer that had worsened after standard treatments. The goal was to see if the drug could shrink tumors and how safe it was. The study is now complet…

This pilot study tested the drug Tislelizumab given before surgery in 12 people with early-stage lung cancer who also had multiple ground-glass nodules on CT scans. The goal was to see if the drug could shrink tumors before removal. Researchers measured how many patients responde…

This study tracked 109 patients with a specific genetic mutation (MET exon 14 skipping) causing advanced lung cancer who were prescribed Tabrecta tablets. Researchers monitored side effects and how well the drug controlled the cancer over up to one year. The goal was to see how T…

This study tested a new drug called AZD3759 against standard targeted therapies (erlotinib or gefitinib) in 492 people with advanced EGFR-mutant lung cancer that had spread to the brain. The goal was to see if AZD3759, which is designed to better reach the brain, could keep the c…

This early-phase study tested an experimental drug called TPST-1495, taken as a pill, either alone or combined with the immunotherapy Keytruda (pembrolizumab). The trial included 89 people with advanced solid tumors like colorectal, lung, head and neck, and endometrial cancers wh…

This completed study looked at side effects of the lung cancer drug Lorbrena in 1,290 patients. Researchers focused on nervous system problems and liver damage. The goal was to understand what factors might increase these risks during real-world use.

This early-phase trial tested an experimental immunotherapy called ELI-002 in 25 people with KRAS-mutated pancreatic, colorectal, lung, ovarian, or bile duct cancers who had signs of remaining disease after standard treatment. The therapy aims to train the immune system to attack…

This study looked at whether a blood test can find gene changes in people with advanced lung cancer. 22 adults gave a blood sample, and the results were compared to standard tissue tests. The goal was to see if the blood test is a reliable and practical option for guiding treatme…

This study looked at whether a simple blood test (liquid biopsy) can detect EGFR gene mutations in people with advanced non-small cell lung cancer. Researchers collected blood samples from 581 patients and compared the results with standard tissue testing. The goal was to see if …

This study looked at whether a special PET scan (18FDG dual-point) can tell the difference between real tumor growth and harmless inflammation caused by immunotherapy. Researchers studied 100 people with advanced lung cancer or melanoma who were being treated with drugs like nivo…

This study looked at whether adding a special ultrasound procedure (EBUS-TBNA) after a standard PET/CT scan can more accurately stage early-stage non-small cell lung cancer. The 150 participants had stage I or IIa cancer and were being considered for radiation therapy. The goal w…

This study tested a special breathing technique during PET scans to get clearer images of lung tumors. 103 people with small lung nodules (under 35 mm) had both a standard PET scan and an extra scan where they held their breath. The goal was to see if this reduces blurring from b…

This study tested whether a 4-week home exercise program, guided by a wearable fitness device and supervised remotely, could help lung cancer patients get in better shape before surgery. Thirty people with early-stage non-small cell lung cancer participated. The goal was to see i…

This study tested whether a personalized exercise program helps people with early-stage lung cancer or cancer that spread to the lungs recover better after surgery. 182 participants were randomly assigned to either the exercise program or usual care. The main goal was to see if t…

This study tested whether personalized motivational messages sent via apps like WhatsApp could improve thinking skills and physical activity in lung cancer survivors who have memory or concentration problems. 124 survivors wore activity trackers and received custom messages for t…

This study tested an investigational drug called ponsegromab in 187 adults with lung, pancreatic, or colorectal cancer who also had cachexia—a condition causing severe weight loss, loss of appetite, and fatigue. The goal was to see if ponsegromab could help patients gain weight a…

This study tested two different radiotherapy schedules for people with advanced non-small cell lung cancer. One group received the standard 6-week course, while the other had a shorter 4-week course guided by PET scans. The main goal was to see how patients felt during and after …

This study tested whether an education and support program can help family caregivers of cancer patients feel more confident and less anxious. About 484 caregivers and patients took part. Researchers compared different types of support to see which worked best.

This study tested whether a family-supported palliative care program could improve quality of life and emotional well-being in 110 people with advanced lung cancer. Participants were randomly assigned to either the family-supported program or standard nursing care for 8 weeks. Th…

This study tested a low-cost, portable exercise program for people with non-small cell lung cancer after surgery. The goal was to help them manage severe fatigue and improve their quality of life. 235 adults took part, and the program was designed to be safe and practical for nea…

This study tested the safety of a special radiation schedule called Quad Shot for people with stage IV non-small cell lung cancer who are also receiving chemotherapy or immunotherapy. The Quad Shot delivers radiation in just 2 days per cycle, up to 3 cycles, to make it easier to …

This study looked at whether people with non-small cell lung cancer prefer getting the drug atezolizumab as a shot under the skin (subcutaneous) or through an IV drip. About 179 patients tried both methods and reported which they liked better. The goal was to see if the shot is m…

This study tested whether a nutritional supplement with essential amino acids could help lung cancer patients who are losing weight build more protein in their bodies. 41 patients with advanced non-small cell lung cancer took part. The goal was to see if this supplement could red…

This study tested a new bendable surgical tool (SurgeoFlex Grasp) against a standard rigid tool in 100 adults with early-stage lung cancer undergoing keyhole surgery. The goal was to see if the flexible tool makes lymph node removal faster, reduces instrument clashes, and eases s…

This study looked at 30 people with early-stage non-small cell lung cancer who had surgery. Researchers collected blood from a vein near the tumor and from a regular arm vein to study tiny particles called exosomes. The goal was to see if these particles could help predict whethe…

This completed study looked at 40,000 people with metastatic cancer who received the drug nivolumab. Researchers compared the old way of dosing (based on body weight) with a newer, simpler fixed dose. They used national health data to see if the fixed dose was just as good and mo…

This completed study looked at 44 patients who had lung cancer surgery to understand how the arteries in the lungs can vary from person to person. Using CT scans and 3D models, researchers mapped these variations to help surgeons avoid complications during lobectomy. The goal was…

This completed study enrolled 336 people with non-small cell lung cancer to collect detailed family cancer histories using a questionnaire. Researchers want to see if certain patterns of cancer in relatives, along with smoking and other risk factors, can help identify patients wh…

This study looked at whether a blood test called ISET can find circulating tumor cells in people with early-stage non-small cell lung cancer. Researchers checked blood samples from 256 patients before surgery to see if these cells were linked to cancer stage, type, and survival. …

This study explored sleep disorders in 37 adults with non-small cell lung cancer. Participants filled out questionnaires about their sleep, symptoms, mood, and quality of life. The goal was to create a guide to help doctors diagnose and treat sleep issues in this group, ultimatel…

This study reviewed medical records of 350 Australian patients with a specific type of advanced lung cancer (EGFR-mutant non-small cell lung cancer). Researchers looked at how long patients stayed on the drug osimertinib when it was given as their first or second treatment, and h…

This study tested whether a special 4D PET-CT scan can help doctors better target radiation for lung cancer. Seven patients with non-small cell lung cancer received both a standard CT scan and a 4D PET-CT scan before radiotherapy. Researchers compared the tumor volumes identified…

This study analyzed blood samples from 50 adults with advanced ALK-positive lung cancer whose disease had stopped responding to one or two ALK inhibitors. The goal was to identify genetic changes in the cancer that cause drug resistance. By matching these changes to the right nex…

This phase 2 trial studied 50 people with non-small cell lung cancer to see if differences within a tumor (called heterogeneity) affect how well treatments work. Patients received one of four drugs based on their tumor's genetic changes: atezolizumab (immunotherapy), vemurafenib,…

This study looked at the nutrition and body composition of 25 adults with non-small-cell lung cancer who were taking the drug osimertinib. Researchers measured weight, muscle mass, and strength to see how common malnutrition and muscle loss were, and how these affected quality of…

This study looked at chemical fingerprints (metabolites) in blood, lung tissue, and exhaled breath from 74 people with either non-small cell lung cancer or harmless lung nodules. The goal was to find differences that could help diagnose lung cancer without invasive procedures. Re…

This study looked back at medical records of 240 adults in Poland who received a combination of two immunotherapy drugs (nivolumab and ipilimumab) plus chemotherapy as their first treatment for advanced non-small cell lung cancer. The goal was to see how well the treatment worked…

This study looks at whether the drug T-DXd works better than standard treatments for people with several types of HER2-positive solid tumors. Researchers will compare data from previous T-DXd trials with real-world medical records of patients who received standard care. The goal …

This study looked back at medical records of 60 people with advanced non-small cell lung cancer who received standard immunotherapy (anti-PD-1/PD-L1 drugs). Researchers checked whether those who also took beta-blockers (commonly used for heart conditions) had different outcomes, …

This study looked at whether people with advanced cancers (melanoma, kidney, or lung cancer) receiving their first immunotherapy treatment could successfully collect small blood samples at home using a finger-prick method. The goal was to see if this approach is practical and rel…

This study looked at whether a simple blood test (liquid biopsy) can detect a specific resistance mutation called T790M in patients with advanced non-small cell lung cancer whose tumors stopped responding to initial targeted therapy. Researchers followed 70 patients in Tunisia, c…

This study examined pieces of the Met receptor protein in tumor and healthy tissue from 56 people with non-small cell lung cancer. Researchers used blood and tissue samples taken during surgery or biopsy to see which Met fragments are present and whether they are active. The goal…

This study created a detailed database of 518 adults with non-small cell lung cancer in the Nord Pas de Calais region of France. Researchers collected clinical information and genetic mutation data to see how factors like age, smoking, and cancer stage relate to specific mutation…

This study looked back at the medical records of 833 people with advanced non-small cell lung cancer to understand how they were treated and how long they lived. Researchers collected information from doctors' surveys across multiple countries. The goal was to learn about real-wo…

This completed phase 1 study in 28 healthy adults examines how the experimental cancer drug calderasib (MK-1084) changes the way the body processes two common drugs: midazolam and digoxin. Researchers measure drug levels in the blood after giving these drugs with and without cald…

This study looked at the safety and effectiveness of the drug Vizimpro in 188 adults with advanced lung cancer who had specific gene mutations. It was an observational study, meaning patients received their normal treatment and researchers simply collected data on side effects an…

This study aimed to find immune-related biomarkers that could predict how well patients with non-small cell lung cancer respond to the drug atezolizumab. Researchers analyzed blood and tumor samples from 100 participants to track immune cell changes and genetic markers. The goal …

This study tested a screening platform to check tumor tissue for specific biomarkers. The goal was to see if patients with solid tumors could be eligible for a linked Roche clinical trial. About 470 participants provided tumor samples for testing. The study is now complete and fo…

This completed study looked at nearly 5,000 people with non-small cell lung cancer to see if information from electronic health records could produce the same results as a famous clinical trial called FLAURA. Researchers compared patients who started taking osimertinib to those o…

This study looked at whether the time of day affects the number of cancer cells in the blood of people with advanced lung cancer. Researchers took blood samples from 27 patients at 4 a.m. and 10 a.m. before starting treatment. The goal was to see if circadian rhythms influence ho…

This study followed 196 people with advanced lung or stomach cancer who had not yet received treatment. Researchers wanted to see if emotional distress before starting immunotherapy, along with certain blood markers of inflammation and metabolism, could predict how long patients …

This study looked at 98 adults with cancers like melanoma and lung cancer who were starting immunotherapy. Researchers measured inflammatory markers in their blood to understand how the body reacts to these drugs. The goal was to find ways to better manage side effects from treat…

This study looked at 40 people with advanced non-small cell lung cancer who were starting treatment with the drug pembrolizumab. Researchers used special PET scans after each of the first three doses to see how the cancer's metabolism changed. The goal was to find out if early sc…

This study looked at whether a special type of PET scan called parametric imaging can better predict if lung cancer will come back within a year after chemoradiation. Researchers compared it to standard PET scans in 40 patients with non-small cell lung cancer. The goal is to see …

This study tested a new blood test (liquid biopsy) to find cancer markers in 135 people with head and neck, lung, or skin cancer. The goal was to see if the blood test works as well as a standard tissue biopsy. The study did not provide treatment but aimed to improve how doctors …

This study tested whether a combination of 6 markers from tumor tissue could predict how well patients with advanced non-small cell lung cancer respond to first-line treatment with pembrolizumab (immunotherapy) plus chemotherapy. Researchers analyzed tissue samples from 106 patie…

This completed study observed 178 patients with advanced cancer, chronic kidney failure, or chronic lung diseases to assess their palliative care needs and survival factors. Researchers used two scoring tools to evaluate when and how to best introduce palliative care alongside re…

This study looked at 212 adults with advanced non-small cell lung cancer who received the drug nivolumab after chemotherapy. Researchers tracked how many patients were still alive 12, 24, and 36 months after starting treatment. The goal was to see how well the drug works in every…

This study looked at how the lung cancer drug AZD9291 (osimertinib) affects the breakdown of simvastatin, a common cholesterol medicine, in 52 adults with a specific type of advanced lung cancer (EGFR mutation-positive NSCLC) that had stopped responding to earlier treatments. The…

This study looked at 62 people with ALK-positive lung cancer whose tumors had stopped responding to newer targeted drugs. Instead of a tissue biopsy, researchers used a blood test (liquid biopsy) to find genetic changes that cause resistance. The goal was to better understand the…